RSS
10 Nov 2019

Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

Author: admintech | Filed under: Press Release

SAN DIEGO, Nov. 9, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in metastatic…

This entry was posted on Sunday, November 10th, 2019 at 7:33 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»